Diligence memo · auto-generated · as of July 2, 2026
Nexus Biologics, SPC
Nexus Biologics, SPC looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Nexus Biologics, SPC operates in Biotech / Pharma, based in SEATTLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nexus Biologics, SPC has raised $146K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $146K on 2019-03-04.
Most recent recorded round closed around 2019-03-04.
Valuation (modeled)modeled
Provath models Nexus Biologics, SPC at approximately $7.5M (range $80K–$85M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.46× the median modeled value of Pre-Seed Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era. Within the normal band (146% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 7.3 yr ago; this sector typically re-raises about every 15 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 10% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 30% of those peers.
Closest niche peers: AbX Biologics, Inc., BC Green Pharmaceuticals Inc., Platinum Biosciences, Inc., Anubis Bio Corp., Green Star Biosciences Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.